Program News
News and stories about members of the UNC Lineberger Molecular Therapeutics Research Program
-
Devising a smarter way to treat brain tumors
Shawn Hingtgen, PhD, and his lab team have developed a method they call a “slice platform” that may help clinicians choose the best treatment for their brain tumor patients.
-
Getting to the heart of chemotherapeutic cardiotoxicity
Brian Jensen, MD, sees cancer patients who have developed, or are at risk of developing, heart damage in response to their chemotherapy regimens.
-
Lindsey James: Building a career, one molecule at a time
Lindsey James, PhD, is well-suited to the collaborative relationship between UNC Lineberger and UNC Eshelman School of Pharmacy, taking her interests in medicinal chemistry and epigenetics and working with cancer center physicians and researchers to make strides into cancer care and treatment.
-
UNC Lineberger and UNC researchers discuss latest research at American Society of Hematology Annual Meeting
UNC Lineberger researchers will present the latest findings from studies and lead educational sessions at the 64th American Society of Hematology Annual Meeting in New Orleans, Dec. 10-13.
-
UNC Lineberger faculty recognized as world’s most highly cited researchers
Twelve UNC Lineberger Comprehensive Cancer Center members were named to Clarivate’s 2022 Highly Cited Researchers list.
-
UNC Lineberger creates RNA Discovery Center
The UNC RNA Discovery Center, led by Chad Pecot, MD, will cultivate an inclusive community of scientists dedicated to investigating all aspects of RNA biology.
-
Implant churns out CAR-T cells to combat cancer in animal models
Yevgeny Brudno, PhD, and colleagues from NC State University and UNC-Chapel Hill have developed an implantable biotechnology that produces and releases CAR-T for attacking cancerous tumors.
-
Four UNC Lineberger members elected AAAS fellows
Four UNC Lineberger members have been elected 2021 fellows of the American Association for the Advancement of Science, one of the most distinct honors in the scientific community.
-
New vulnerability found in lung squamous cancer may facilitate drug targeting at the cellular level
New research by Chad Pecot, MD, and colleagues shows the potential for targeting a specific circular RNA, known as CDR1as, to attack lung squamous cell cancer.
-
Cox honored with Mentor Award for Lifetime Achievement
The University Committee on Teaching Awards has selected UNC Lineberger’s Adrienne Cox, PhD, as a recipient of the Mentor Award for Lifetime Achievement.
-
Wang published in the journal Small
Andrew Z. Wang, MD, was corresponding author of a paper evaluating whether nanoparticle drug delivery contributed to liver damage, or hepatotoxicity.
-
Der lab publishes in Cancer Discovery
UNC Lineberger’s Channing Der, PhD, Sarah Graham Kenan Distinguished Professor in the UNC School of Medicine Department of Pharmacology, was co-corresponding author of a paper published in Cancer Discovery. Antje Schaefer, PhD, research assistant professor in the UNC School of Medicine Department of Pharmacology, was co-first author. In the study, researchers identified a new potential … Continued
-
NCBiotech awards grant to Pecot for studies of experimental RNAi therapy
The North Carolina Biotechnology Center awarded $100,000 to UNC Lineberger Comprehensive Cancer Center’s Chad Pecot, MD, to study an experimental treatment that would silence a gene commonly mutated in cancer. Using a Nobel Prize-winning technology called RNA interference or RNAi, Pecot’s lab designed an investigational drug to shut down the mutated version of the KRAS … Continued
-
Researchers find KRAS gene mutation differences have implications for pancreatic cancer treatment
The KRAS gene is commonly mutated in cancer. In the journal Cancer Discovery, researchers led by Channing Der, PhD, and Aaron Hobbs, PhD, reported details of the role of the KRAS G12R mutation in pancreatic cancer, and therapeutic strategies that might work for this mutation type. By studying unique differences in DNA mutations within the same gene, researchers are working to uncover the mutation-specific mechanisms that drive cancerous growth.
-
NCI awards $1.68M grant to James to study gene important to childhood cancers
The NCI has awarded more than $1.68 million across five years to UNC Lineberger’s Lindsey James, PhD, to study a gene that can control how other genes are expressed in cells, and when dysregulated, can lead to cancer.